Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

An oral platelet-activating factor antagonist, Ro-24-4736, protects the rat kidney from ischemic injury

An oral platelet-activating factor antagonist, Ro-24-4736, protects the rat kidney from ischemic... K. J. KELLY, NINA E. TOLKOFF-RUBIN, ROBERT H. RUBIN, WINFRED W. WILLIAMS, JR., SHANE M. MEEHAN, CAROL L. MESCHTER, JAMES G. CHRISTENSON, AND JOSEPH V. BONVENTRE Medical and Pathology Services, Massachusetts General Hospital, Departments of Medicine and Pathology, Harvard Medical School, Boston, Massachusetts 02114; Center for Experimental Pharmacology and Therapeutics, Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, Cambridge, Massachusetts 02139; and Roche Research Center, Hoffmann-La Roche, Nutley, New Jersey 07110 Kelly, K. J., Nina E. Tolkoff-Rubin, Robert H. Rubin, Winfred W. Williams, Jr., Shane M. Meehan, Carol L. Meschter, James G. Christenson, and Joseph V. Bonventre. An oral platelet-activating factor antagonist, Ro-244736, the rat kidney from . Am. J. Physiol. 271 (RenaZ FZuid Electrolyte Physiol. 40): F1061F1067, 1996.-The role of platelet-activating factor (PAF) in acute failure was evaluated by administering an oral PAF antagonist (Ro-24-4736) to rats prior to or after interruption of blood flow to both kidneys for 30 min. In animals treated with the PAF antagonist prior to ischemia, function was less impaired and histological abnormalities was less pronounced when compared with post kidneys from vehicle-treated animals. Serum creatinine (mg/ dl) 24 h following ischemia was 1.58 ? 0.17 in the PAF antagonist-treated http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AJP - Renal Physiology The American Physiological Society

An oral platelet-activating factor antagonist, Ro-24-4736, protects the rat kidney from ischemic injury

Loading next page...
 
/lp/the-american-physiological-society/an-oral-platelet-activating-factor-antagonist-ro-24-4736-protects-the-BXvIkfZrhX

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
The American Physiological Society
Copyright
Copyright © 1996 the American Physiological Society
ISSN
0363-6127
eISSN
1522-1466
Publisher site
See Article on Publisher Site

Abstract

K. J. KELLY, NINA E. TOLKOFF-RUBIN, ROBERT H. RUBIN, WINFRED W. WILLIAMS, JR., SHANE M. MEEHAN, CAROL L. MESCHTER, JAMES G. CHRISTENSON, AND JOSEPH V. BONVENTRE Medical and Pathology Services, Massachusetts General Hospital, Departments of Medicine and Pathology, Harvard Medical School, Boston, Massachusetts 02114; Center for Experimental Pharmacology and Therapeutics, Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, Cambridge, Massachusetts 02139; and Roche Research Center, Hoffmann-La Roche, Nutley, New Jersey 07110 Kelly, K. J., Nina E. Tolkoff-Rubin, Robert H. Rubin, Winfred W. Williams, Jr., Shane M. Meehan, Carol L. Meschter, James G. Christenson, and Joseph V. Bonventre. An oral platelet-activating factor antagonist, Ro-244736, the rat kidney from . Am. J. Physiol. 271 (RenaZ FZuid Electrolyte Physiol. 40): F1061F1067, 1996.-The role of platelet-activating factor (PAF) in acute failure was evaluated by administering an oral PAF antagonist (Ro-24-4736) to rats prior to or after interruption of blood flow to both kidneys for 30 min. In animals treated with the PAF antagonist prior to ischemia, function was less impaired and histological abnormalities was less pronounced when compared with post kidneys from vehicle-treated animals. Serum creatinine (mg/ dl) 24 h following ischemia was 1.58 ? 0.17 in the PAF antagonist-treated

Journal

AJP - Renal PhysiologyThe American Physiological Society

Published: Nov 1, 1996

There are no references for this article.